SCHEMBL4780599

SCHEMBL4780599

Cc1cccc(Cc2c(C)nc3c(C(=O)NCCN)cnn3c2C)c1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 12/20 0.70
TP53 P04637 11/20 0.70
MAPT P10636 7/20 0.70
KDM4E B2RXH2 7/20 0.70
ALDH1A1 P00352 7/20 0.70
HPGD P15428 6/20 0.70
SMN1; SMN2 Q16637 4/20 0.70
NPSR1 Q6W5P4 4/20 0.70
HSD17B10 Q99714 3/20 0.70
HTT P42858 3/20 0.70
MEN1 O00255 3/20 0.70
KMT2A Q03164 3/20 0.70
USP2 O75604 1/20 0.70
TSHR P16473 1/20 0.70
ALOX12 P18054 1/20 0.70
MAPK1 P28482 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4725554 0.85 LMNA (0.63) LMNATP53MAPTKDM4EALDH1A1
SCHEMBL4782331 0.85 HSD17B10 (0.74) LMNATP53MAPTKDM4EALDH1A1
SCHEMBL4778108 0.82 LMNA (0.59) LMNATP53MAPTKDM4EALDH1A1
SCHEMBL4794039 0.81 KDM4E (0.61) LMNATP53MAPTKDM4EALDH1A1
SCHEMBL4782391 0.81 KDM4E (0.61) LMNATP53MAPTKDM4EALDH1A1
SCHEMBL4796367 0.81 KDM4E (0.63) LMNATP53MAPTKDM4EALDH1A1
SCHEMBL4725695 0.81 LMNA (0.59) LMNATP53MAPTKDM4EALDH1A1
SCHEMBL4942505 0.81 KDM4E (0.63) LMNATP53MAPTKDM4EALDH1A1
SCHEMBL4793664 0.81 KDM4E (0.78) LMNATP53MAPTKDM4EALDH1A1
SCHEMBL4779338 0.81 KDM4E (0.72) LMNATP53MAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221129-A1 New compounds BIOVITRUM AB (PUBL) (SE) 2008-09-11 US disclosed
WO-2008003753-A1 PYRAZOLO [1,5-A] PYRIMIDINE ANALOGS FOR USE AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) ACTIVITY BIOVITRUM AB (PUBL) (SE) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221129-A1 New compounds SCD, SCD5, FASN LMNA 2075/4885TP53 1572/4885MAPT 168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.